Cargando…

Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies

Liver cirrhosis, a late stage of hepatic fibrosis, is an increasing cause of morbidity and mortality worldwide. Hepatic fibrosis is mainly caused by alcoholic or non-alcoholic steatohepatitis, chronic viral hepatitis, or autoimmune and biliary diseases. Myofibroblasts, which are absent from the norm...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwaisako, Keiko, Taura, Kojiro, Koyama, Yukinori, Takemoto, Kenji, Asagiri, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223535/
https://www.ncbi.nlm.nih.gov/pubmed/25401051
http://dx.doi.org/10.1007/s40139-014-0057-8
_version_ 1782343211824447488
author Iwaisako, Keiko
Taura, Kojiro
Koyama, Yukinori
Takemoto, Kenji
Asagiri, Masataka
author_facet Iwaisako, Keiko
Taura, Kojiro
Koyama, Yukinori
Takemoto, Kenji
Asagiri, Masataka
author_sort Iwaisako, Keiko
collection PubMed
description Liver cirrhosis, a late stage of hepatic fibrosis, is an increasing cause of morbidity and mortality worldwide. Hepatic fibrosis is mainly caused by alcoholic or non-alcoholic steatohepatitis, chronic viral hepatitis, or autoimmune and biliary diseases. Myofibroblasts, which are absent from the normal liver, are differentiated from heterogeneous cell populations in response to a liver injury of any etiology and produce the extracellular matrix. Hepatic stellate cells are considered the main source of myofibroblasts. However, the origin of hepatic myofibroblasts remains unresolved, and despite considerable research, only a limited success has been achieved by existing anti-fibrotic therapies. The question remains whether these limitations are caused by lack of attention to the critical targets, the myofibroblasts derived from cells of other mesenchymal origins. Therefore, identifying the origin of myofibroblasts may provide insight into the mechanisms underlying liver fibrosis, and may lead to the development of more effective therapies. This review will examine our current strategies for detecting hepatic myofibroblasts of different origins.
format Online
Article
Text
id pubmed-4223535
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-42235352014-11-12 Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies Iwaisako, Keiko Taura, Kojiro Koyama, Yukinori Takemoto, Kenji Asagiri, Masataka Curr Pathobiol Rep Myofibroblast (Tatiana Kisseleva, Section Editor) Liver cirrhosis, a late stage of hepatic fibrosis, is an increasing cause of morbidity and mortality worldwide. Hepatic fibrosis is mainly caused by alcoholic or non-alcoholic steatohepatitis, chronic viral hepatitis, or autoimmune and biliary diseases. Myofibroblasts, which are absent from the normal liver, are differentiated from heterogeneous cell populations in response to a liver injury of any etiology and produce the extracellular matrix. Hepatic stellate cells are considered the main source of myofibroblasts. However, the origin of hepatic myofibroblasts remains unresolved, and despite considerable research, only a limited success has been achieved by existing anti-fibrotic therapies. The question remains whether these limitations are caused by lack of attention to the critical targets, the myofibroblasts derived from cells of other mesenchymal origins. Therefore, identifying the origin of myofibroblasts may provide insight into the mechanisms underlying liver fibrosis, and may lead to the development of more effective therapies. This review will examine our current strategies for detecting hepatic myofibroblasts of different origins. Springer US 2014-09-14 2014 /pmc/articles/PMC4223535/ /pubmed/25401051 http://dx.doi.org/10.1007/s40139-014-0057-8 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Myofibroblast (Tatiana Kisseleva, Section Editor)
Iwaisako, Keiko
Taura, Kojiro
Koyama, Yukinori
Takemoto, Kenji
Asagiri, Masataka
Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies
title Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies
title_full Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies
title_fullStr Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies
title_full_unstemmed Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies
title_short Strategies to Detect Hepatic Myofibroblasts in Liver Cirrhosis of Different Etiologies
title_sort strategies to detect hepatic myofibroblasts in liver cirrhosis of different etiologies
topic Myofibroblast (Tatiana Kisseleva, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223535/
https://www.ncbi.nlm.nih.gov/pubmed/25401051
http://dx.doi.org/10.1007/s40139-014-0057-8
work_keys_str_mv AT iwaisakokeiko strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies
AT taurakojiro strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies
AT koyamayukinori strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies
AT takemotokenji strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies
AT asagirimasataka strategiestodetecthepaticmyofibroblastsinlivercirrhosisofdifferentetiologies